Healthcare -
Biotechnology - NASDAQ - US
$ 5.53
-3.66 %
$ 10.6 M
Market Cap
-0.17
P/E
1. INTRINSIC VALUE
Balance Sheet
Bolt Biotherapeutics, Inc.
| Current Assets | 50.8 M |
| Cash & Short-Term Investments | 47.3 M |
| Receivables | 1.16 M |
| Other Current Assets | 2.33 M |
| Non-Current Assets | 48.8 M |
| Long-Term Investments | 22.9 M |
| PP&E | 24.9 M |
| Other Non-Current Assets | 1.04 M |
| Current Liabilities | 15.9 M |
| Accounts Payable | 1.51 M |
| Short-Term Debt | 2.25 M |
| Other Current Liabilities | 12.1 M |
| Non-Current Liabilities | 26.6 M |
| Long-Term Debt | 45.9 M |
| Other Non-Current Liabilities | -19.3 M |
EFFICIENCY
Earnings Waterfall
Bolt Biotherapeutics, Inc.
| Revenue | 7.69 M |
| Cost Of Revenue | 0 |
| Gross Profit | 5.51 M |
| Operating Expenses | 80.7 M |
| Operating Income | -73 M |
| Other Expenses | -9.93 M |
| Net Income | -63.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bolt Biotherapeutics, Inc.
| Net Income | -63.1 M |
| Depreciation & Amortization | 1.78 M |
| Capital Expenditures | -41 K |
| Stock-Based Compensation | 7.41 M |
| Change in Working Capital | -8.44 M |
| Others | -7.36 M |
| Free Cash Flow | -61.3 M |
Wall Street Analysts Price Targets
Bolt Biotherapeutics, Inc.
BOLT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
BOLT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Bolt Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.48 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)
Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,971 shares of the company’s stock, valued at approximately $26,000. Squarepoint Ops LLC owned about 0.13% of Bolt Biotherapeutics as of its most recent SEC filing. Separately, Millennium Management LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at approximately $25,000. Institutional investors own 86.70% of the company’s stock. Bolt Biotherapeutics Stock Performance Shares of BOLT opened at $6.64 on Wednesday. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market cap of $254.58 million, a PE ratio of -3.88 and a beta of 0.91. The company’s 50 day simple moving average is $6.76 and its 200-day simple moving average is $8.90. Bolt Biotherapeutics, Inc. has a 12-month low of $5.20 and a 12-month high of $15.60. Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($5.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.80) by $1.00. The business had revenue of $1.22 million for the quarter, compared to analyst estimates of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. As a group, equities analysts predict that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current year. Wall Street Analysts Forecast Growth Several equities analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a “hold” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday, March 25th. Finally, Lake Street Capital initiated coverage on shares of Bolt Biotherapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $80.00 target price on the stock. Check Out Our Latest Stock Analysis on BOLT Bolt Biotherapeutics Profile (Free Report) Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
https://www.defenseworld.net
- 1 month ago
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.28 per share a year ago.
zacks.com
- 2 months ago
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We continue to make progress advancing our pipeline of first-in-class, novel immunotherapies,” said Willie Quinn, Chief Executive Officer. “We recently presented promising early clinical data for BDC-3042 at AACR and launched a process to find a partner to accelerate BDC-3042 development. We also just opened enrollment for the first next-generation Boltbody™ ISAC in our pipeline, BDC-4182. We are excited to see what our ISAC platform technology can do for gastric and gastroesophageal cancer patients. We continue to be good stewards of capital as we execute against our mission to deliver new treatment options to patients with cancer.”
globenewswire.com
- 2 months ago
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting.
globenewswire.com
- 2 months ago
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events
globenewswire.com
- 2 months ago
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
globenewswire.com
- 3 months ago
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update.
globenewswire.com
- 4 months ago
Bolt Biotherapeutics to Participate in Upcoming March Conferences
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care Conference Company presentation on Tuesday, March 4, 2025 at 3:10 p.m.
globenewswire.com
- 4 months ago
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development and License Agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform technology. Bolt plans to co-develop and jointly commercialize the resulting ISAC product candidate with Toray.
globenewswire.com
- 5 months ago
CSE Bulletin: Stock Split - Bolt Metals Corp. (BOLT)
Toronto, Ontario--(Newsfile Corp. - Le 11 novembre/November 2024) - Bolt Metals Corp. has announced a two (2) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive one (1) additional share for each share held on such date.
newsfilecorp.com
- 8 months ago
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024.
globenewswire.com
- 8 months ago
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
accesswire.com
- 10 months ago
8. Profile
Summary
Bolt Biotherapeutics, Inc. BOLT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 10.6 M
Dividend Yield
0.00%
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Contact
900 Chesapeake Drive, Redwood City, CA, 94063
https://www.boltbio.com
IPO
Date
Feb. 5, 2021
Employees
52
Officers
Mr. Grant Yonehiro C.F.A., M.B.A.
Chief Operating Officer & Chief Business Officer
Dr. Nathan Ihle Ph.D.
Senior Vice President of Pharmaceutical Operations
Mr. William P. Quinn
Chief Executive Officer, Chief Financial Officer, President, Secretary & Director
Ms. Sarah Nemec
Senior Vice President of Finance & Principal Accounting Officer
Mr. Wesley Burwell
Vice President & Head of Human Resources
Dr. Michael N. Alonso Ph.D.
Senior Vice President of Research